85274-48-2

Usage

InChI:InChI=1/C15H9BrClN/c16-12-6-7-14-11(8-12)9-13(15(17)18-14)10-4-2-1-3-5-10/h1-9H

Upstream product

• 113092-91-4 6-bromo-3,4-dihydro-3-phenylcarbostyril 
• 110486-57-2 6-bromo-3-phenylquinolin-2(1H)-one 
• 1022-66-8 3-phenyl-1,2,3,4-tetrahydro-2-quinolone 
• 19319-35-8 (E)-2-phenyl-3-(2-nitrophenyl)propenoic acid 
• 106-40-1 4-bromo-aniline 
• 7495-11-6 N-(4-bromophenyl)-2-phenylacetamide 
• 68-12-2 N,N-dimethyl-formamide 
• 5332-25-2 6-bromoquinoline 
• 916429-26-0 6-bromo-2-chloro-3-iodoquinoline 
• 98-80-6 phenylboronic acid 
• 103-80-0 phenylacetyl chloride 

Downstream Products

• 113093-02-0 2-[4-(6-Bromo-3-phenyl-quinolin-2-yl)-piperazin-1-yl]-ethanol 
• 861872-60-8 C₂₆H₂₂BrClF₂N₂O 
• 1600563-50-5 C₂₇H₂₂ClN₃O₂ 
• 1413416-55-3 6-bromo-2-methoxy-3-phenylquinoline 
• 113093-01-9 6-Bromo-2-(4-methyl-piperazin-1-yl)-3-phenyl-quinoline 

Relevant academic research and scientific papers

Identification and structure activity relationships of quinoline tertiary alcohol modulators of RORγt

A high-throughput screen of the ligand binding domain of the nuclear receptor retinoic acid-related orphan receptor gamma t (RORγt) employing a thermal shift assay yielded a quinoline tertiary alcohol hit. Optimization of the 2-, 3- and 4-positions of the quinoline core using structure-activity relationships and structure-based drug design methods led to the discovery of a series of modulators with improved RORγt inhibitory potency and inverse agonism properties.

Structural Simplification of Bedaquiline: the Discovery of 3-(4-(N,N-Dimethylaminomethyl)phenyl)quinoline-Derived Antitubercular Lead Compounds

Bedaquiline (BDQ) is a novel and highly potent last-line antituberculosis drug that was approved by the US FDA in 2013. Owing to its stereo-structural complexity, chemical synthesis and compound optimization are rather difficult and expensive. This study

PHENYL LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also

PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T

The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The inve

HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

Synthesis and 5-Hydroxytryptamine Antagonist Activity of 2-thio>-3-phenylquinoline and Its Analogues

A series of 2-quinolines substituted at the 3-position with alkyl, aryl, or heteroaryl groups has been prepared in the search for novel and selective 5-HT2 antagonists.The affinity of the compounds for 5-HT1 recep